TWI854088B - 用於治療腎臟疾病之抗αｖβ８整聯蛋白抗體 - Google Patents

用於治療腎臟疾病之抗αｖβ８整聯蛋白抗體 Download PDF

Info

Publication number
TWI854088B
TWI854088B TW110101209A TW110101209A TWI854088B TW I854088 B TWI854088 B TW I854088B TW 110101209 A TW110101209 A TW 110101209A TW 110101209 A TW110101209 A TW 110101209A TW I854088 B TWI854088 B TW I854088B
Authority
TW
Taiwan
Prior art keywords
antibody
renal
αvβ8 integrin
αvβ8
antigen
Prior art date
Application number
TW110101209A
Other languages
English (en)
Chinese (zh)
Other versions
TW202140554A (zh
Inventor
大衛 詹姆士 貝克
史黛芬妮 克萊兒 希斯曼
瑪麗亞 馬塞拉 赫雷拉
艾蓮娜 莉亞特 馬林
奎恩 卡洛 派翠西亞 莫雷諾
琳恩 安妮 莫瑞
平 崔
艷麗 鄔
Original Assignee
英商梅迪繆思有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 英商梅迪繆思有限公司 filed Critical 英商梅迪繆思有限公司
Publication of TW202140554A publication Critical patent/TW202140554A/zh
Application granted granted Critical
Publication of TWI854088B publication Critical patent/TWI854088B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70546—Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
TW110101209A 2020-01-27 2021-01-13 用於治療腎臟疾病之抗αｖβ８整聯蛋白抗體 TWI854088B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062966258P 2020-01-27 2020-01-27
US62/966,258 2020-01-27

Publications (2)

Publication Number Publication Date
TW202140554A TW202140554A (zh) 2021-11-01
TWI854088B true TWI854088B (zh) 2024-09-01

Family

ID=74561850

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110101209A TWI854088B (zh) 2020-01-27 2021-01-13 用於治療腎臟疾病之抗αｖβ８整聯蛋白抗體

Country Status (18)

Country Link
US (1) US20230112035A1 (https=)
EP (1) EP4096785A1 (https=)
JP (1) JP7706458B2 (https=)
KR (1) KR20220132567A (https=)
CN (1) CN115151305A (https=)
AR (1) AR121193A1 (https=)
AU (1) AU2021213403B2 (https=)
BR (1) BR112022014633A2 (https=)
CA (1) CA3167390A1 (https=)
CL (1) CL2022001999A1 (https=)
CO (1) CO2022011661A2 (https=)
CR (1) CR20220392A (https=)
EC (1) ECSP22066085A (https=)
IL (1) IL294814A (https=)
MX (1) MX2022009165A (https=)
PH (1) PH12022551863A1 (https=)
TW (1) TWI854088B (https=)
WO (1) WO2021151889A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11359024B2 (en) 2018-09-07 2022-06-14 Pfizer Inc. Anti-AVB8 antibodies and compositions and uses thereof
US20260035468A1 (en) 2022-09-12 2026-02-05 Institut National de la Santé et de la Recherche Médicale New anti-itgb8 antibodies and its uses thereof
TW202446789A (zh) * 2023-03-31 2024-12-01 美商建南德克公司 抗αｖβ８整合素抗體及使用方法
CN117143241B (zh) * 2023-10-26 2024-02-23 迈威(上海)生物科技股份有限公司 与人整合素蛋白itgav/itgb8特异性结合的单克隆抗体
CN117126282B (zh) * 2023-10-26 2024-01-12 迈威(上海)生物科技股份有限公司 抗体及其在制备阻断αvβ8与Latent TGF-β的结合的药物中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013026004A2 (en) * 2011-08-17 2013-02-21 The Regents Of The University Of California Antibodies that bind integrin alpha-v beta-8

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
MX342270B (es) * 2010-02-18 2016-09-21 The Regents Of The Univ Of California * ANTICUERPO NEUTRALIZANTE DE LA INTEGRINA AVß8.
US20170073406A1 (en) * 2014-05-06 2017-03-16 Scholar Rock, Inc. Compositions and methods for growth factor modulation
PT3157561T (pt) 2014-06-17 2020-03-25 Univ California Anticorpos contra alfa-v beta-8 melhorados
EP3634485A4 (en) * 2017-06-07 2021-07-21 Silverback Therapeutics, Inc. CONJUGATES OF ANTIBODIES CONTAINING IMMUNOMODULATOR COMPOUNDS AND THEIR USES
CA3112523A1 (en) * 2018-08-08 2020-02-13 The General Hospital Corporation Integrin antagonists

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013026004A2 (en) * 2011-08-17 2013-02-21 The Regents Of The University Of California Antibodies that bind integrin alpha-v beta-8

Also Published As

Publication number Publication date
CR20220392A (es) 2022-09-07
JP7706458B2 (ja) 2025-07-11
CO2022011661A2 (es) 2022-08-30
CN115151305A (zh) 2022-10-04
TW202140554A (zh) 2021-11-01
JP2023511686A (ja) 2023-03-22
PH12022551863A1 (en) 2024-01-03
AU2021213403B2 (en) 2025-04-10
WO2021151889A1 (en) 2021-08-05
KR20220132567A (ko) 2022-09-30
ECSP22066085A (es) 2022-09-30
CA3167390A1 (en) 2021-08-05
MX2022009165A (es) 2022-08-16
EP4096785A1 (en) 2022-12-07
AU2021213403A1 (en) 2022-09-15
BR112022014633A2 (pt) 2022-09-13
AR121193A1 (es) 2022-04-27
IL294814A (en) 2022-09-01
CL2022001999A1 (es) 2023-01-27
US20230112035A1 (en) 2023-04-13

Similar Documents

Publication Publication Date Title
TWI854088B (zh) 用於治療腎臟疾病之抗αｖβ８整聯蛋白抗體
JP7842703B2 (ja) 抗Ｃｌａｕｄｉｎ１８．２抗体およびその使用
US10202454B2 (en) Anti-PD-L1 monoclonal antibodies and fragments thereof
EP2167542B1 (en) Neutralizing monoclonal antibody against human dll4
KR101869413B1 (ko) Ｓ100ａ4 항체들 및 이들의 치료 용도
NO334834B1 (no) Anti-alfavbeta6-antistoff, celle som produserer slikt antistoff, samt anvendelse av antistoffet for fremstilling av medikamenter
KR20210142638A (ko) Cd3 항원 결합 단편 및 이의 응용
TWI756621B (zh) 新型雙特異性抗體分子以及同時結合pd-l1和lag-3的雙特異性抗體
JP2021011493A (ja) ＭＡｄＣＡＭアンタゴニストの投与レジメン
WO2020151761A1 (zh) 结合pd-l1和ox40的双特异性抗体
US12258409B2 (en) Method of assessing the efficacy of a test agent for modulating programmed death 1 (PD-1) signaling by using anti-phosphotyrosinylated PD-1 monoclonal antibodies
WO2021249542A1 (en) Antibodies binding tnfr2 and uses thereof
JP2023528002A (ja) Ｔ細胞を選択的に調節するための二重特異性分子
TWI743469B (zh) 抗ｇｉｔｒ抗體及其用途
WO2023145844A1 (ja) 抗ヒトｃｘｃｌ１抗体
EA049172B1 (ru) АНТИТЕЛА К ИНТЕГРИНУ αvβ8 ДЛЯ ПРИМЕНЕНИЯ ПРИ ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ ПОЧЕК
WO2026078647A1 (en) Combination of trispecific antibody targeting bcma, gprc5d and cd3, and pomalidomide for the treatment of multiple myeloma
HK1207093A1 (en) Anti-robo4-antibody
HK1207093B (en) Anti-robo4-antibody